Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer

A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes

(2016) Young Kwang Chae et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Management of toxicities of immune checkpoint inhibitors

(2016) Lavinia Spain et al.   CANCER TREATMENT REVIEWS

Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 Diabetes

(2016) Yuka Miyoshi et al.   TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE

Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy

(2016) Masahide Okamoto et al.   Journal of Diabetes Investigation

Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy

(2016) Jared R. Lowe et al.   Journal for ImmunoTherapy of Cancer

Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report

(2015) Juan Martin-Liberal et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Anti–PD-1 and Anti–PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes

(2015) Mahnaz Mellati et al.   DIABETES CARE

Anti-PD1 Pembrolizumab Can Induce Exceptional Fulminant Type 1 Diabetes

(2015) Caroline Gaudy et al.   DIABETES CARE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Blockade of the Programmed Death-1 (PD1) Pathway Undermines Potent Genetic Protection from Type 1 Diabetes

(2014) Nora M. Kochupurakkal et al.   PLoS One

Genetics of the HLA Region in the Prediction of Type 1 Diabetes

(2011) Janelle A. Noble et al.   Current Diabetes Reports

ZnT8 autoantibody titers in type 1 diabetes patients decline rapidly after clinical onset

(2010) Fariba Vaziri-Sani et al.   AUTOIMMUNITY